Renaissance Technologies’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $188M | Sell |
421,688
-83,360
| -17% | -$38.9M | 0.29% | 54 |
|
|
2025
Q4 | $229M | Sell |
505,048
-230,840
| -31% | -$99.5M | 0.36% | 43 |
|
|
2025
Q3 | $288M | Sell |
735,888
-269,000
| -27% | -$112M | 0.38% | 38 |
|
|
2025
Q2 | $447M | Sell |
1,004,888
-166,683
| -14% | -$76.8M | 0.6% | 20 |
|
|
2025
Q1 | $568M | Sell |
1,171,571
-225,638
| -16% | -$105M | 0.86% | 8 |
|
|
2024
Q4 | $563M | Sell |
1,397,209
-234,284
| -14% | -$109M | 0.83% | 7 |
|
|
2024
Q3 | $759M | Buy |
1,631,493
+65,105
| +4% | +$31.3M | 1.14% | 5 |
|
|
2024
Q2 | $734M | Sell |
1,566,388
-14,100
| -0.9% | -$6.12M | 1.25% | 4 |
|
|
2024
Q1 | $661M | Sell |
1,580,488
-11,200
| -0.7% | -$4.73M | 1.04% | 6 |
|
|
2023
Q4 | $648M | Sell |
1,591,688
-72,400
| -4% | -$26.7M | 1% | 7 |
|
|
2023
Q3 | $579M | Buy |
1,664,088
+391,927
| +31% | +$137M | 0.99% | 7 |
|
|
2023
Q2 | $448M | Sell |
1,272,161
-125,574
| -9% | -$42.3M | 0.65% | 16 |
|
|
2023
Q1 | $440M | Sell |
1,397,735
-849,017
| -38% | -$255M | 0.58% | 17 |
|
|
2022
Q4 | $649M | Buy |
2,246,752
+107,867
| +5% | +$32.9M | 0.89% | 7 |
|
|
2022
Q3 | $619M | Buy |
2,138,885
+377,717
| +21% | +$109M | 0.88% | 6 |
|
|
2022
Q2 | $496M | Buy |
1,761,168
+53,800
| +3% | +$14.4M | 0.59% | 18 |
|
|
2022
Q1 | $446M | Buy |
1,707,368
+80,500
| +5% | +$19.1M | 0.52% | 26 |
|
|
2021
Q4 | $357M | Sell |
1,626,868
-264,618
| -14% | -$51.5M | 0.44% | 37 |
|
|
2021
Q3 | $343M | Sell |
1,891,486
-385,798
| -17% | -$75.3M | 0.44% | 36 |
|
|
2021
Q2 | $459M | Sell |
2,277,284
-123,000
| -5% | -$25.7M | 0.57% | 25 |
|
|
2021
Q1 | $516M | Sell |
2,400,284
-1,175,646
| -33% | -$258M | 0.64% | 18 |
|
|
2020
Q4 | $845M | Sell |
3,575,930
-1,631,002
| -31% | -$374M | 0.92% | 10 |
|
|
2020
Q3 | $1.42B | Sell |
5,206,932
-574,400
| -10% | -$158M | 1.41% | 4 |
|
|
2020
Q2 | $1.68B | Sell |
5,781,332
-1,078,350
| -16% | -$292M | 1.45% | 6 |
|
|
2020
Q1 | $1.63B | Sell |
6,859,682
-216,900
| -3% | -$49.8M | 1.59% | 3 |
|
|
2019
Q4 | $1.55B | Buy |
7,076,582
+1,277,465
| +22% | +$259M | 1.19% | 4 |
|
|
2019
Q3 | $982M | Buy |
5,799,117
+243,300
| +4% | +$43M | 0.83% | 8 |
|
|
2019
Q2 | $1.02B | Buy |
5,555,817
+477,100
| +9% | +$83.4M | 0.9% | 5 |
|
|
2019
Q1 | $934M | Buy |
5,078,717
+744,417
| +17% | +$137M | 0.85% | 5 |
|
|
2018
Q4 | $718M | Buy |
4,334,300
+245,183
| +6% | +$42.5M | 0.79% | 8 |
|
|
2018
Q3 | $788M | Buy |
4,089,117
+38,500
| +1% | +$6.86M | 0.81% | 9 |
|
|
2018
Q2 | $688M | Buy |
4,050,617
+1,199,700
| +42% | +$186M | 0.75% | 11 |
|
|
2018
Q1 | $465M | Buy |
2,850,917
+3,000
| +0.1% | +$490K | 0.51% | 18 |
|
|
2017
Q4 | $427M | Buy |
2,847,917
+1,479,897
| +108% | +$219M | 0.47% | 23 |
|
|
2017
Q3 | $208M | Buy |
1,368,020
+1,346,320
| +6,204% | +$203M | 0.24% | 69 |
|
|
2017
Q2 | $2.8M | Sell |
21,700
-18,417
| -46% | -$2.22M | ﹤0.01% | 2067 |
|
|
2017
Q1 | $4.39M | Buy |
+40,117
| New | +$3.53M | 0.01% | 1770 |
|
|
2016
Q3 | – | Sell |
-60,517
| Closed | -$5.21M | – | 3504 |
|
|
2016
Q2 | $5.21M | Sell |
60,517
-52,100
| -46% | -$4.5M | 0.01% | 1572 |
|
|
2016
Q1 | $8.95M | Buy |
112,617
+51,300
| +84% | +$4.64M | 0.02% | 1223 |
|
|
2015
Q4 | $7.72M | Buy |
+61,317
| New | +$7.4M | 0.02% | 1167 |
|
|
2015
Q2 | – | Sell |
-159,317
| Closed | -$18.8M | – | 3401 |
|
|
2015
Q1 | $18.8M | Buy |
+159,317
| New | +$19.1M | 0.04% | 610 |
|
|
2014
Q2 | – | Sell |
-312,164
| Closed | -$22.1M | – | 2989 |
|
|
2014
Q1 | $22.1M | Buy |
+312,164
| New | +$24.7M | 0.05% | 449 |
|
|
2013
Q4 | – | Sell |
-139,220
| Closed | -$10.6M | – | 3042 |
|
|
2013
Q3 | $10.6M | Buy |
+139,220
| New | +$11.1M | 0.03% | 771 |
|
Other funds holding VRTX
VCM
VPM
Renaissance Technologies's VRTX Position: Q1 2026 in Review
Renaissance Technologies reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, selling an estimated $38.9M and leaving 421,688 shares worth $188M. The position accounts for 0.29% of the portfolio, ranked #54.
Renaissance Technologies first reported a position in VRTX in Q3 2013 and has held it in 43 quarters since. The position peaked at $1.68B in Q2 2020. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Renaissance Technologies held 421,688 shares of Vertex Pharmaceuticals worth $188M as of Q1 2026.
- Renaissance Technologies sold 83,360 Vertex Pharmaceuticals shares in Q1 2026, an estimated $38.9M.
- Vertex Pharmaceuticals made up 0.29% of Renaissance Technologies's portfolio in Q1 2026, its #54 holding.
- Renaissance Technologies first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 43 quarters since.
- Renaissance Technologies's Vertex Pharmaceuticals position peaked at $1.68B in Q2 2020.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.